Journal of Obstetrics and Gynaecology Research最新文献

{"title":"Correction to “Comparative Evaluation of Clinical Outcomes and Aneuploidy Risk Between Day 5 and Day 6 Blastocyst: A Retrospective Study”","authors":"","doi":"10.1111/jog.70485","DOIUrl":"10.1111/jog.70485","url":null,"abstract":"<p>\u0000 <span>L. Xie</span>, <span>R. Wu</span>, <span>L. Lai</span>, and <span>Y. Chen</span>, “ <span>Comparative Evaluation of Clinical Outcomes and Aneuploidy Risk Between Day 5 and Day 6 Blastocyst: A Retrospective Study</span>,” <i>Journal of Obstetrics and Gynaecology Research</i> <span>52</span>, no. <span>5</span> (<span>2026</span>): e70303, https://doi.org/10.1111/jog.70303.\u0000 </p><p>The affiliation of the corresponding author Yan Chen was incorrect and has been corrected to “Department of Reproductive Medicine, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.”</p><p>The online version of this article has been corrected accordingly.</p><p>We apologize for this error.</p>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13551115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to “Effectiveness of a 1-h Reproductive Health Lecture on Enhancing Fertility Knowledge Among Japanese Female Undergraduates”","authors":"Jun Takeda,&nbsp;Kyoko Namimatsu","doi":"10.1111/jog.70487","DOIUrl":"10.1111/jog.70487","url":null,"abstract":"","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Isolated Maternal Hypothyroxinemia and Adverse Maternal and Infant Outcomes","authors":"Wenlei Zhang,&nbsp;Shixuan Liu,&nbsp;Jianlan Zheng,&nbsp;Wenyan Wang,&nbsp;Xuejing Ding","doi":"10.1111/jog.70488","DOIUrl":"10.1111/jog.70488","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The current meta-analysis aims to assess the incidence of isolated maternal hypothyroxinemia (IMH) and its impact on pregnancy complications and adverse pregnancy outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, Embase, Web of Science, and Cochrane databases were searched until November 15, 2024. Cochrane, a risk-of-bias assessment tool, was used to evaluate the quality of literature; R Studio and Stata 15.0 were employed for data analysis and publication bias assessment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 22 cohort studies were analyzed, with a sample size of 33,1640 cases, including 16 390 IMH patients. The meta-analysis revealed that the prevalence of IMH was 5.7% (95% CI: 3.5, 8.4%). Compared to pregnant women with normal thyroid function, the prevalence of gestational diabetes mellitus (GDM) in IMH patients was 1.12% (95% CI: 1.01,1.24), macrosomia was 1.41% (95% CI: 1.12, 1.65), preterm birth was 1.26% (95% CI: 1.12, 1.41), and preeclampsia/eclampsia was 1.26% (95% CI: 1.12, 1.41) (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with IMH have an elevated risk of GDM, preeclampsia, eclampsia, preterm birth, and macrosomia relative to normal pregnant women. It is anticipated that future studies will further confirm the complications related to pregnancy in patients with IMH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Weekly Paclitaxel–Carboplatin-Based Chemoradiotherapy Versus Cisplatin-Based Chemoradiotherapy for FIGO Stage IB2–IVA Cervical cancer: A Retrospective Observational Study","authors":"Ayano Shimizu,&nbsp;Kenro Chikazawa,&nbsp;Yukiko Fukuda,&nbsp;Ken Imai,&nbsp;Katsuyuki Shirai,&nbsp;Tomoyuki Kuwata","doi":"10.1111/jog.70489","DOIUrl":"10.1111/jog.70489","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>We compared outcomes and toxicities of weekly paclitaxel plus carboplatin-based (wTC) and cisplatin-based (CDDP) concurrent chemoradiotherapy (CCRT) in FIGO stage IB2–IVA cervical cancer cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed patients with FIGO stage IB2–IVA cervical cancer who underwent definitive-intent CCRT at our institution between 2009 and 2024. To reduce temporal confounding, the primary analysis was restricted to 2015–2024, when both regimens were available, and a sensitivity analysis included the entire period. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan–Meier method and Cox proportional hazards models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The primary analysis included 54 patients (wTC, <i>n</i> = 27; CDDP, <i>n</i> = 27). Baseline characteristics were balanced. The 3-year PFS rates were 53.5% and 77.4% in the wTC and CDDP groups, respectively (<i>p</i> = 0.078), and the 3-year OS rates were 76.4% and 75.4%, respectively (<i>p</i> = 0.882). The treatment regimen was not significantly associated with OS, whereas tumor diameter ≥ 6 cm was associated with worse OS. In the sensitivity analysis (wTC, <i>n</i> = 84; CDDP, <i>n</i> = 27), PFS and OS did not differ significantly between groups. Creatinine increased was more severe in the CDDP group, whereas neutropenia was more severe in the wTC group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>No significant differences in survival outcomes were observed between wTC-CCRT and CDDP-CCRT in patients with FIGO stage IB2–IVA cervical cancer. The study was not designed to establish equivalence or non-inferiority. wTC-CCRT may be considered for selected patients unable to receive cisplatin, although its comparative efficacy remains uncertain.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic ALK-Positive Inflammatory Myofibroblastic Tumor Presenting 8 Years After Uterine Smooth Muscle Tumor of Uncertain Malignant Potential","authors":"Aleah R. Singleton,&nbsp;Shuang R. Chen,&nbsp;Michelle M. De Jesus Ortiz,&nbsp;Monika A. Rak,&nbsp;Carley Knudsen,&nbsp;Ridin Balakrishnan,&nbsp;Lucio Miele,&nbsp;Tara Castellano,&nbsp;Sun Young Kim","doi":"10.1111/jog.70495","DOIUrl":"10.1111/jog.70495","url":null,"abstract":"<div>\u0000 \u0000 <p>Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm with intermediate biologic potential that rarely involves the female genital tract. Distinguishing IMT from other pelvic spindle cell tumors can be challenging, particularly in patients with a prior history of uterine smooth muscle neoplasms. We report a 59-year-old woman who underwent hysterectomy for a smooth muscle tumor of uncertain malignant potential and presented 8 years later with recurrent small bowel obstruction and right flank pain. Imaging revealed a large infiltrative pelvic mass involving ovaries, ureter, small bowel, peritoneum, and iliac vessels. She underwent extensive multidisciplinary surgery, including small bowel resection, right nephrectomy, and vascular reconstruction. Histopathologic examination demonstrated a fascicular proliferation of spindle cells associated with a prominent lymphoplasmacytic inflammatory infiltrate. Diffuse anaplastic lymphoma kinase (ALK) expression was identified by immunohistochemistry, and fluorescence in situ hybridization demonstrated an <i>ALK</i> rearrangement, supporting the diagnosis of ALK-positive IMT. Identification of the <i>ALK</i> rearrangement directly influenced treatment selection and enabled initiation of ALK-targeted therapy. This case highlights the diagnostic challenges posed by pelvic spindle cell neoplasms in a patient with a history of uterine smooth muscle neoplasms and underscores the importance of integrating morphologic, immunohistochemical, and molecular findings to establish an accurate diagnosis and guide targeted therapy.</p>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Dose Corticosteroids in Chronic Histiocytic Intervillositis Allowing Prolongation of Pregnancy: A Case Report","authors":"Arti Dave,&nbsp;Victoria Bryant,&nbsp;Manlo Kwok,&nbsp;Rebecca Allen,&nbsp;Alexander Heazell,&nbsp;Kate Wiles","doi":"10.1111/jog.70478","DOIUrl":"10.1111/jog.70478","url":null,"abstract":"<p>Chronic histiocytic intervillositis (CHI) is a rare placental disorder linked to poor pregnancy outcomes, including fetal growth restriction and perinatal loss. We report a case of recurrent CHI in a 36-year-old woman with five previous pregnancy losses. In her sixth pregnancy, placental histology confirmed CHI after preterm delivery. In a subsequent seventh pregnancy, despite early treatment with aspirin, low-molecular weight heparin, and hydroxychloroquine, she developed uteroplacental dysfunction at 17 weeks with hypertension, proteinuria, and transaminitis. Rescue therapy with high-dose prednisolone led to maternal clinical improvement, stabilization of fetal Dopplers, and pregnancy prolongation to 30 weeks. Placental histology showed a reduced inflammatory infiltrate compared to the prior pregnancy, suggesting a therapeutic effect from corticosteroids. This case reports the novel use of high-dose corticosteroid rescue therapy in managing CHI and highlights the importance of early diagnosis, multidisciplinary care, and the need for further research.</p>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13550697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2023 and Annual Treatment Report for 2018","authors":"Hiroaki Kajiyama,&nbsp;Satoshi Tamauchi,&nbsp;Fumiaki Takahashi,&nbsp;Toyomi Satoh,&nbsp;Board members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology","doi":"10.1111/jog.70476","DOIUrl":"10.1111/jog.70476","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2023 and the Annual Treatment Report for 2018 on the outcomes of patients who started treatment in 2018.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2023 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2018 was analyzed by using the Kaplan–Meier, log-rank, and Wilcoxon tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Treatment was initiated in 2023 for 8061 patients with cervical cancer, 15 455 with endometrial cancer, 8844 with ovarian, tubal, and peritoneal cancer, 2316 with ovarian borderline tumors, and with the others (230 vulvar cancer, 157 vaginal cancer, 533 uterine sarcoma, 54 uterine adenosarcoma, 132 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2018 were as follows. For cervical cancer, the rates were 92.6%, 75.7%, 57.3%, and 25.9% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.3%, 88.3%, 75.2%, and 32.1% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 90.9%, 79.2%, 53.4%, and 41.1% for Stages I, II, III, and IV, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Pregnancy and Early-Pregnancy Risk Factors for Placental Abruption: A Nationwide Retrospective Cohort Study in Japan","authors":"Kei Takehara,&nbsp;Masato Takeuchi,&nbsp;Seiichiro Yamamoto,&nbsp;Katsuya Owaki,&nbsp;Yoshiho Masui,&nbsp;Aki Kamo,&nbsp;Takakazu Kawamura,&nbsp;Yoko Sato","doi":"10.1111/jog.70486","DOIUrl":"10.1111/jog.70486","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To identify pre- and early-pregnancy risk factors for placental abruption using a nationwide perinatal registry in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We evaluated 1 706 721 singleton pregnancies delivered at ≥ 22 weeks' gestation during 2014–2023 in the Japan Society of Obstetrics and Gynecology perinatal registry. Primary analysis: multivariable binary logistic regression estimated adjusted odds ratios (aORs) with 95% confidence intervals for placental abruption, adjusting for 56 prespecified baseline covariates. Secondary analysis: multinomial logistic regression accounted for preterm birth as a competing pregnancy outcome. Exploratory analyses: a conditional inference tree explored risk-factor combinations; multinomial and within-case binary logistic regression compared abruption with and without intrauterine fetal death (IUFD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Placental abruption occurred in 16 016 pregnancies (0.94%). History of placental abruption (aOR 5.80) and hypertensive disorders of pregnancy (aOR 1.54), pre-existing essential hypertension (aOR 1.77), advanced maternal age, low pre-pregnancy body mass index (BMI), smoking during pregnancy, and velamentous (aOR 2.36) and marginal (aOR 1.76) cord insertions were independently associated with increased odds of abruption; associations were largely consistent in the multinomial analysis, and abnormal umbilical cord insertion was the primary splitting variable. Established risk factors were shared between abruption with and without IUFD, whereas smoking, higher BMI, and previous cesarean delivery were more strongly associated with the IUFD subtype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Established maternal vascular and obstetric risk factors were associated with placental abruption and largely shared across subtypes defined by IUFD status. Abnormal umbilical cord insertion was also associated with abruption, suggesting that abnormal placental development may be related to the pathogenesis of this condition.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creatine Kinase as a Potential Diagnostic Biomarker for Distinguishing Placenta Accreta Spectrum and Placenta Previa: A Prospective Pilot Study","authors":"Lulu Wang,&nbsp;Tianjiao Liu,&nbsp;Liwen Yang,&nbsp;Xinyu Xiao,&nbsp;Jiaxin Chen,&nbsp;Limin Wang","doi":"10.1111/jog.70472","DOIUrl":"10.1111/jog.70472","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Placenta previa (PP) and placenta accreta spectrum (PAS) are major causes of severe obstetric hemorrhage, yet in some scenarios, antenatal discrimination and risk stratification remain challenging with imaging alone. An inexpensive, widely available adjunct biomarker such as maternal serum creatine kinase (CK) may help differentiate PP from PAS, reflect imaging-based placental severity, and identify women at increased risk of intraoperative massive hemorrhage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This pilot prospective cohort study enrolled women with singleton pregnancies managed at a tertiary center between January 2025 and January 2026 with suspected PP or PAS. PP and PAS were confirmed by intraoperative inspection and postoperative histopathology. Serum CK was measured using third-trimester blood samples. Ultrasound and MRI placental scores were calculated using predefined scoring systems. Spearman correlation assessed associations between CK and imaging scores. Multivariable logistic regression explored risk factors for intraoperative massive hemorrhage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-one participants were included (PP, <i>n</i> = 22; PAS, <i>n</i> = 9). Late-gestation CK levels were significantly higher in PAS than PP (78.28 ± 30.01 vs. 38.07 ± 17.86 U/L; <i>p</i> = 0.041). PAS had higher ultrasound and MRI placental scores than PP (both <i>p</i> &lt; 0.001). CK was moderately positively correlated with the ultrasound score (<i>ρ</i> = 0.484, <i>p</i> = 0.003) and MRI score (<i>ρ</i> = 0.401, <i>p</i> = 0.026). In multivariable analyses, higher CK, more prior cesarean deliveries, and higher ultrasound and MRI scores were associated with increased odds of intraoperative massive hemorrhage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Late-gestation maternal serum CK was elevated in PAS versus PP, correlated with ultrasound- and MRI-based placental scores, and was associated with massive hemorrhage risk, suggesting CK as a potential adjunct biomarker for PAS.</p>\u0000 \u0000 <p><b>Trial registration:</b> ChiCTR2100054068, December 8, 2021.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menstrual Recovery and Reproductive Outcomes After Fertility-Sparing Surgery and Adjuvant Chemotherapy for Malignant Ovarian Germ Cell Tumors: A Retrospective Cohort Study","authors":"Aroontorn Pichatechaiyoot,&nbsp;Rakchai Buhachat,&nbsp;Wanapa Naphatthalung,&nbsp;Nungrutai Saeaib,&nbsp;Kanet Kanjanapradit","doi":"10.1111/jog.70462","DOIUrl":"10.1111/jog.70462","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate menstrual recovery, reproductive outcomes, and survival following fertility-sparing surgery and platinum-based chemotherapy in women with malignant ovarian germ cell tumors (MOGCTs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed women aged 15–40 years with MOGCT treated at a university hospital (2001–2012). All underwent fertility-sparing surgery and platinum-based chemotherapy. Menstrual and reproductive outcomes were assessed through structured interviews and compared with age-matched controls. Survival outcomes were analyzed by Kaplan–Meier method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1934 ovarian cancer cases, 209 (10.8%) were MOGCT; 44 patients met inclusion criteria and were matched to 44 controls. Median age was 21 years; dysgerminoma was the most common histology (40.9%), and 70.4% had Stage I disease. All received bleomycin, etoposide, and cisplatin (median 4 cycles). After a median follow-up of 55 months, 97.7% resumed menstruation. Compared with baseline and controls, cycles were shorter (4 vs. 5 days, <i>p</i> = 0.026), lighter (2 vs. 3 pads/day, <i>p</i> = 0.004–0.047), and longer in interval (29.2 vs. 26.4 days, <i>p</i> &lt; 0.001). Of 17 patients attempting conception, 9 achieved 10 pregnancies, with a pregnancy rate of 52.9% and live-birth rate of 90.9%, without congenital anomalies. Only one recurrence occurred, with 10-year progression-free and overall survival of 95.3% and 97.9%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Fertility-sparing surgery followed by platinum-based chemotherapy was associated with excellent long-term survival, high rates of menstrual recovery, and favorable reproductive outcomes in young women with MOGCT. These findings support current international recommendations for fertility-preserving treatment in selected patients and provide long-term evidence from a Southeast Asian cohort.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"52 9","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}